Rebus (RBSH) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'GENSPERA INC	'
Entity Central Index Key	'0001421204	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'GNSZ	'
Entity Common Stock, Shares Outstanding	'	32,522,311
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$4,791	$3,587
Prepaid expenses	174	163
Total current assets	4,965	3,750
Office equipment, net of accumulated depreciation of $19 and $16	13	14
Intangible assets, net of accumulated amortization of $103 and $94	110	118
Other assets	3	3
Total assets	5,091	3,885
Current liabilities:	'	'
Accounts payable	1,170	1,270
Accrued expenses	982	1,250
Convertible notes - stockholder	105	105
Total current liabilities	2,257	2,625
Total liabilities	2,257	2,625
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, par value $0.0001 per share; 30,000,000 shares authorized, none issued and outstanding	0	0
Common stock, par value $0.0001 per share; 150,000,000 shares authorized, 32,522,311 and 27,252,966 shares issued and outstanding, respectively	3	3
Additional paid-in capital	38,761	33,642
Accumulated deficit	-35,930	-32,385
Total stockholders’ equity	2,834	1,260
Total liabilities and stockholders’ equity	$5,091	$3,885

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Office equipment, accumulated depreciation (in dollars)	$19	$16
Intangible assets, accumulated amortization (in dollars)	$103	$94
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	32,522,311	27,252,966
Common stock, shares outstanding	32,522,311	27,252,966

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
General and administrative	$682	$682	$1,518	$1,423
Research and development	924	792	2,028	1,582
Total operating expenses	1,606	1,474	3,546	3,005
Loss from operations	-1,606	-1,474	-3,546	-3,005
Gain on change in fair value of warrant derivative liability	0	531	0	766
Interest income (expense), net	1	-1	1	-2
Loss before provision for income taxes	-1,605	-944	-3,545	-2,241
Provision for income taxes	0	0	0	0
Net loss	($1,605)	($944)	($3,545)	($2,241)
Net loss per common share, basic and diluted (in dollars per share)	($0.06)	($0.04)	($0.13)	($0.10)
Weighted average shares outstanding (in shares)	28,705,705	23,759,386	28,012,097	23,299,517

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Private Placement [Member]	Common Stock	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital	Common Stock Subscribed	Common Stock Subscribed	Accumulated Deficit	Accumulated Deficit
In Thousands, except Share data				Private Placement [Member]		Private Placement [Member]		Private Placement [Member]		Private Placement [Member]
Balance at Dec. 31, 2013	$1,260	'	$3	'	$33,642	'	$0	'	($32,385)	'
Balance (in shares) at Dec. 31, 2013	'	'	27,252,966	'	'	'	'	'	'	'
Stock based compensation	1,109	'	0	'	1,109	'	0	'	0	'
Common stock and warrants issued as payment of services and consulting fees	233	'	0	'	233	'	0	'	0	'
Common stock and warrants issued as payment of services and consulting fees (in shares)	'	'	139,134	'	'	'	'	'	'	'
Sale of common stock and warrants at $0.80 per share	3,331	773	0	0	3,331	773	0	0	0	0
Sale of common stock and warrants at $0.80 per share (in shares)	'	'	4,163,961	966,250	'	'	'	'	'	'
Issuance cost of sales of common stock and warrants	-327	'	0	'	-327	'	0	'	0	'
Net loss	-3,545	'	0	'	0	'	0	'	-3,545	'
Balance at Jun. 30, 2014	$2,834	'	$3	'	$38,761	'	$0	'	($35,930)	'
Balance (in shares) at Jun. 30, 2014	'	'	32,522,311	'	'	'	'	'	'	'

STATEMENT_OF_STOCKHOLDERS_EQUI1

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	Jun. 30, 2014
Shares Issued, Price Per Share	$0.80
Private Placement [Member]	'
Shares Issued, Price Per Share	$0.80

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($3,545)	($2,241)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	12	12
Stock-based compensation	1,342	1,148
Change in fair value of derivative liability	0	-766
Increase in operating assets:	'	'
Prepaid expenses	-11	-117
Increase in operating liabilities:	'	'
Accounts payable and accrued expenses	-369	-185
Cash used in operating activities	-2,571	-2,149
Cash flows from investing activities:	'	'
Acquisition of office equipment	-2	-8
Cash used in investing activities	-2	-8
Cash flows from financing activities:	'	'
Proceeds from sale of common stock and warrants	4,104	1,217
Proceeds from exercise of warrants	0	217
Cost of common stock and warrants sold	-327	-122
Cash provided by financing activities	3,777	1,312
Net increase (decrease) in cash	1,204	-845
Cash, beginning of period	3,587	2,345
Cash, end of period	$4,791	$1,500

BACKGROUND

BACKGROUND	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	NOTE 1 – BACKGROUND
	GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform.
	Our primary focus at the present time is the clinical development of our lead compound, G-202, a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of G-202, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We are conducting a Phase II clinical trial of G-202 in patients with liver cancer, in which twenty-one patients have been treated as of July 23, 2014. In July 2014, we presented interim results from our Phase Ib and our ongoing Phase II study in liver cancer patients which indicated that 80% of patients treated with G-202 had stable disease (no tumor growth) at two months, and 50% of patients exhibited stable disease at 4 months on study. These results support our plans to continue to develop G-202 for patients with liver cancer, as well as proceed with our clinical development strategy in other indications including glioblastoma, prostate cancer and renal cell carcinoma trials. Notwithstanding that the initial and interim data from our trials appear promising, the outcome of our trials is uncertain and our current or future trials may ultimately be unsuccessful.
	We are also currently conducting a Phase II clinical trial in glioblastoma (a type of brain cancer), in which four patients have been treated as of July 23, 2014.

MANAGEMENTS_PLANS_TO_CONTINUE_

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	6 Months Ended
	Jun. 30, 2014
Management Plans to Continue as Going Concern [Abstract]	'
Management Plans to Continue as Going Concern Disclosure [Text Block]	'
	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN
	Basis of Presentation
	We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have a deficit accumulated of $35.9 million as of June 30, 2014. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates currently in development or we enter into cash flow positive business development transactions.
	To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance G-202 through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in research and development of pharmaceutical compounds.
	Our cash and cash equivalents balance at June 30, 2014 was $4.8 million, representing 94% of our total assets. Based upon our current expected level of operating expenditures, we expect to be able to fund our operations for the next 12 to 18 months. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated significant increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available when needed to allow us to continue our operations, or if available, on terms acceptable to us.
	In the event financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue in existence.

SUMMARY_OF_CRITICAL_ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES
	Use of estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.
	Research and Development
	Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses.
	We incurred research and development expenses of approximately $0.9 million and $0.8 million for the three months ended June 30, 2014 and 2013, respectively. We incurred research and development expenses of approximately $2.0 million and $1.6 million for the six months ended June 30, 2014 and 2013, respectively.
	Loss per Share
	Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of June 30, 2014 and 2013, as they would be anti-dilutive:
			Six months ended June 30,
			2014		2013
	Shares underlying options outstanding			8,462,895		5,961,641
	Shares underlying warrants outstanding			20,510,987		8,089,520
	Shares underlying convertible notes outstanding			265,894		257,072
				29,239,776		14,308,233
	Fair Value of Financial Instruments
	Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.
	Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. We use the Black-Scholes option-pricing model to value our warrant derivative liability which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
	Fair Value Measurements
	Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:
	Level 1:	Quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2:	Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
	Level 3:	Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
	A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. We previously recorded a warrant derivative liability for warrants with non-standard anti-dilution provisions. These warrants were either exercised or expired as of June 30, 2014.
	Stock-Based Compensation
	We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).
	Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period.
	Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
	Reclassifications
	Certain prior year balances have been reclassified to conform to current year presentation.
	Recent Accounting Pronouncements
	In June 2014, the FASB issued ASU 2014-10 Development Stage Entities (Topic 915). ASU 2014-10 removes all incremental financial reporting requirements from U.S. GAAP for development stage entities. ASU 2014-10 should be applied retrospectively and is effective for fiscal years beginning after December 15, 2014. Early application is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued or made available for issuance. Accordingly, we have decided to adopt ASU 2014-10 early, accordingly all of the past disclosures and presentations for development stage accounting have been eliminated.

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Jun. 30, 2014
Supplemental Cash Flow Information [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION
	The following table contains additional information for the periods reported (in thousands):
		Six months ended June 30,
		2014		2013
	Non-cash financial activities:
	Common stock options issued as payment of accrued compensation	$	962	$	999
	Derivative liability reclassified to equity upon exercise of warrants		–		55
	There was no cash paid for interest and income taxes for the three or six months ended June 30, 2014 and 2013.

ACCRUED_EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 5 – ACCRUED EXPENSES
	Accrued expenses consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Accrued compensation and benefits	$	595	$	1,040
	Accrued research and development		184		82
	Accrued other		203		128
	Total accrued expenses	$	982	$	1,250

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended
	Jun. 30, 2014
Notes Payable Disclosure [Abstract]	'
Notes Payable Disclosure [Text Block]	'
	NOTE 6 – CONVERTIBLE NOTES PAYABLE
	We previously entered into convertible notes with our chief executive officer pursuant to which we borrowed an aggregate of $0.2 million, with $0.1 million principal balance outstanding at June 30, 2014. The notes, which bear interest at a rate of 4.2% per annum and matured at various dates through December 6, 2011, are now considered due on demand. As of June 30, 2014, our chief executive officer has not demanded the payment of the outstanding principal and accrued interest. Accrued interest at June 30, 2014 and December 31, 2013 was approximately $28,000 and $26,000, respectively. The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $0.50 per share.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 7 – COMMITMENTS AND CONTINGENCIES
	Legal Matters
	On March 12, 2012, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka (“Mhaka”) in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.). In that complaint, GenSpera, as the licensee of the inventions described and claimed in the U.S. Patent No. 7,468,354 (“the ‘354 patent”) and U.S. Patent No. 7,767,648 (“the ‘648 patent”), sought a declaratory judgment that Mhaka (a former doctoral student at Johns Hopkins University) should not be added to either the ‘354 patent or the ‘648 patent as an inventor. On April 2, 2012, Mhaka filed and served her answer and counterclaim, in which she sought to be added as an inventor to the ‘354 patent and the ‘648 patent pursuant to 35 U.S.C. sec. 256. Between April 26, 2012 and October 1, 2012, the parties conducted fact discovery. Between October 1, 2012 and December 1, 2012, the parties conducted limited expert discovery. On November 1, 2012, Mhaka filed a separate complaint in the State Circuit Court for Baltimore County, Maryland, naming GenSpera as a defendant along with Dr. Samuel Denmeade and Dr. John Isaacs (the named inventors on the ‘354 patent and the ‘648 patent). In the complaint, Mhaka alleged that the defendants are liable under various state law tort theories for the same alleged conduct that formed the basis for her prior inventorship claim. In her prayer for relief, Mhaka sought unspecified damages from the defendants but did not seek to alter the inventorship or ownership of the ‘354 patent or ‘648 patent. On November 8, 2012, the defendants removed this second action to the United States District Court for the District of Maryland, and on November 16, 2012, the defendants moved to dismiss all claims in the complaint, asserting (among other things) that the claims were preempted by federal patent law.
	On January 24, 2013, the Court heard GenSpera’s motion for summary judgment in the original case and the defendants’ motion to dismiss in the second case. On May 1, 2013, the Court granted GenSpera’s motion for summary judgment in the original case. In its order, the Court stated that it would proceed to issue a declaratory judgment establishing that Mhaka should not be added to the two patents at issue as an additional inventor pursuant to 35 U.S.C. § 256. Reserving any ruling on the issue of whether Mhaka’s state law tort claims are preempted by federal patent law, the Court denied defendants’ motion to dismiss Mhaka’s complaint and directed Mhaka to re-file her claims as counterclaims in the original action. On May 14, 2013, Mhaka filed an amended answer and counterclaims in the consolidated action, re-pleading her tort claims as counterclaims. On June 3, 2013, GenSpera (along with Drs. Denmeade and Isaacs) filed a reply to the counterclaims, denying their allegations and raising a number of affirmative defenses. Fact discovery was completed on December 13, 2013, and expert discovery was completed on March 28, 2014. On January 2, 2014, Drs. Isaacs and Denmeade moved for summary judgment on the grounds that Mhaka’s claims are barred by the applicable statute of limitations, and GenSpera joined in the motion. The briefing on that motion is now complete. GenSpera filed a separate motion for summary judgment on May 6, 2014. Mhaka’s opposition to that motion was filed on May 28, 2014. GenSpera’s reply brief in support of the motion was filed on June 16, 2014. GenSpera’s summary judgment motions are now fully briefed. Further scheduling, as appropriate, is to be set after resolution of summary judgment motions.

CAPITAL_STOCK_AND_STOCKHOLDERS

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY
	Common Stock
	In February 2014, we entered into an agreement with H.C. Wainwright to serve as our exclusive placement agent, advisor and underwriter for a proposed offering of our securities. Pursuant to the placement agent agreement, we agreed to pay the placement agent a placement fee equal to 8% of the aggregate gross proceeds to us from the sale of our securities in an offering and to issue the placement agent warrants to purchase shares of common stock equal to 8% of the common stock sold in such offering (excluding shares of common stock issuable upon exercise of any warrants issued in this offering), provided that, with respect to sales to certain prior investors, we agreed to pay the placement agent a fee of 4% of the aggregate proceeds from such prior investors and issue the placement agent warrants equal to 4% of the common stock sold to such investors. In June 2014, we completed an offering of our securities, see Equity Financing section below for further information regarding this transaction.
	In February 2014, we entered into an agreement for method development by a contract manufacturer and issued an aggregate of 91,334 shares of common stock, valued at approximately $127,000, as compensation. In February 2014, we also entered into an agreement to grant an aggregate of 47,800 shares of common stock, valued at approximately $67,000, to a consultant for business advisory services to be provided to the Company.
	During the six months ended June 30, 2014, no warrants were exercised into common shares. During the six months ended June 30, 2013, 200,668 warrants were exercised into an equivalent number of common shares for which we received proceeds of approximately $217,000, and one million warrants were exercised on a cashless basis into 537,722 common shares.
	Equity Financing
	On May 23, 2014, our registration statement on Form S-1 (File No. 333-194687) was declared effective by the Securities and Exchange Commission pursuant to which we offered and sold 4,163,961 units, each consisting of (i) one share of our common stock, (ii) one-half of one Series A common stock purchase warrant, (iii) one Series B common stock purchase warrant and (iv) one Series C common stock purchase warrant at a public offering price of $0.80 per unit. The offering commenced as of May 28, 2014 and did not terminate before all of the securities registered in the registration statement were sold. On June 3, 2014, we closed the sale of such securities, resulting in net proceeds to us of approximately  $3.0 million after deducting placement agent fees and expenses of $278,000 and other offering expenses of approximately $64,000, including the reimbursement of placement agent’s counsel of $50,000. The placement agent also received common stock purchase warrants to purchase such number of shares equal to 8% of the shares sold in the offering to investors, or 326,817 placement agent warrants with substantially the same terms as the Series A warrants.
	Each Series A warrant has an exercise price of $1.15 per share, is immediately exercisable and separately transferable from the common shares and expires on the five year anniversary of the date of issuance. Each Series B warrant has an exercise price of $0.85 per share, is immediately exercisable and separately transferable from the common shares and expires on the nine month anniversary of the date of issuance. Each Series C warrant has an exercise price of $0.85 per share, is immediately exercisable and separately transferable from the common shares and will expire on the twelve month anniversary of the date of issuance. The units are not certificated.
	In June 2014, we are also offered and sold 966,250 units in a private placement to certain accredited investors with whom we had a prior relationship or who were shareholders. Each unit was priced at $0.80 and consisted of one share of our common stock, and one-half of one Series D common stock purchase warrant. Each Series D warrant will have an exercise price of $1.15 per share, will be immediately exercisable and separately transferable from the shares and will expire on the five year anniversary of the date of issuance. The units are not certificated.

STOCK_OPTIONS

STOCK OPTIONS	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 9 – STOCK OPTIONS
	The terms of our 2009 Executive Compensation Plan (“2009 Plan”) and our 2007 Equity Compensation Plan (“2007 Plan”) allow for the issuance of up to 6,000,000 shares of common stock each or 12,000,000 in the aggregate. Collectively, the 2009 Plan and 2007 Plan are referred to as “the Plans.”
	Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the three months ended June 30, 2014 and 2013 was approximately $40,000 and $71,000, respectively. Total stock-based compensation expense recognized for the six months ended June 30, 2014 and 2013 was $1,109,000 and $1,148,000, respectively, of which $962,000 and $958,000 was accrued as of December 31, 2013 and 2012, respectively. The following table summarizes stock option activity under the Plans:
				Weighted-		Weighted-average		Aggregate
				average		remaining		intrinsic
		Number of		exercise		contractual term		value (in
		shares		price		(in years)		thousands)
	Outstanding at December 31, 2013		6,050,623	$	1.82
	Granted		2,412,272	$	1.34
	Exercised		—		—
	Forfeited		—		—
	Outstanding at June 30, 2014		8,462,895	$	1.69		4.2	$	147
	Exercisable at June 30, 2014		8,207,750	$	1.7		4.2	$	142
	As of June 30, 2014, there was $0.1 million of total unrecognized compensation cost related to non-vested stock options which vest over time. That cost is expected to be recognized over a weighted-average period of approximately one year. As of June 30, 2014, there was no unrecognized compensation expense related to performance-based, non-vested employee stock options.
	During the six months ended June 30, 2014, we issued options to purchase 1,948,902 and 106,000 shares of common stock to employees and non-employee directors, respectively, under the Plans. Additionally, we issued options to purchase 357,370 shares of common stock to consultants and advisors. During the six months ended June 30, 2013, we issued options to purchase 1,221,972 and 76,000 shares of common stock to employees and non-employee directors, respectively, under the Plans. Additionally, we issued options to purchase 129,041 shares of common stock to consultants and advisors. During the six months ended June 30, 2014 and 2013, no options were exercised.
	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the six months ended June 30, 2014 and 2013:
		Six months ended June 30,
		2014		2013
	Volatility		55.80%		58.90%
	Expected term (years)		3.4		3.9
	Risk-free interest rate		0.50%		0.70%
	Dividend yield		0%		0%

WARRANTS_AND_DERIVATIVE_WARRAN

WARRANTS AND DERIVATIVE WARRANT LIABILITY	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Fair Value [Text Block]	'
	NOTE 10 – WARRANTS AND DERIVATIVE WARRANT LIABILITY
	We account for common stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock by the Company are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the warrant. At June 30, 2014, all outstanding liability-classified warrants were either exercised or had expired.
	Transactions involving our equity-classified warrants are summarized as follows:
						Weighted-		Weighted-average			Aggregate
						average		remaining			intrinsic
		Number of				exercise		contractual term			value (in
			shares			price			(in years)		thousands)
	Outstanding at December 31, 2013			10,216,597		$	2.56
	Granted			11,315,847		$	0.94
	Exercised			—			—
	Forfeited			-1,021,457		$	2.91
	Outstanding at June 30, 2014			20,510,987		$	1.65			2.2	$	692
	Exercisable at June 30, 2014			20,510,987		$	1.65			2.2	$	692
	During the six months ended June 30, 2014, no warrants were exercised. During the six months ended June 30, 2013, 200,668 warrants were exercised into an equivalent number of common shares and 1,000,000 warrants were exercised on a cashless basis into 537,722 common shares. The following table summarizes outstanding common stock purchase warrants as of June 30, 2014:
						Weighted-
						average
		Number of				exercise
			shares			price			Expiration
	Equity–classified warrants
	Issued to consultants			1,163,759		$	2.38		July 2014 through February 2019
	Issued pursuant to 2009 financings			495,059		$	3		July 2014 through September 2014
	Issued pursuant to 2010 financings			1,022,943		$	3.38		January 2015 through May 2015
	Issued pursuant to 2011 financings			1,936,785		$	3.24		January 2016 through April 2016
	Issued pursuant to 2012 financings			296,366		$	3		Dec-17
	Issued pursuant to 2013 financings			4,376,228		$	1.97		December 2017 through August 2023
	Issued pursuant to 2014 financings			11,219,847		$	0.93		March 2015 through June 2019
				20,510,987
	Equity-classified Warrants
	During the six months ended June 30, 2014, in connection with our registered offering, we issued an aggregate of 10,736,722 common stock purchase warrants, including 10,409,905 issued to investors; and 326,817 to the placement agents. The warrants were issued with an exercise prices between $0.85 and $1.15 per share.
	Additionally, we also issued 483,125 common stock purchase warrants to investors in our June 2014 private offering. The warrants have an exercise price of $1.15 per share.
	We also issued warrants to consultants to purchase 96,000 shares of common stock at an exercise price of $3.00 per share. The per share weighted-average fair value of the warrants granted to consultants during 2014 was estimated at $0.41 per share on the date of grant. During the six months ended June 30, 2013, no warrants were issued to consultants. Total stock-based compensation expense of approximately $40,000 and $2,000 was recognized for warrants and included in the statement of operations for the six months ended June 30, 2014 and 2013, respectively.
	During the six months ended June 30, 2013, in connection with the offering of our securities, we issued an aggregate of 776,204 common stock purchase warrants, including: 686,420 pursuant to closings in January 2013 and March 2013; 18,410 to the placement agent; and 71,374 additional warrants issued to investors that participated in the December 2012 closing. All warrants were issued with an exercise price of $3.00 per share.
	Liability-classified Warrants
	We have assessed our outstanding equity-linked financial instruments and have concluded that certain of our warrants are subject to derivative accounting as a result of certain non-standard anti-dilution provisions contained in the warrants. The fair value of these warrants is classified as a liability in our financial statements with the change in fair value during the periods presented, recorded in the statement of operations. At June 30, 2014, all outstanding liability-classified warrants were either exercised or had expired.
	We did not record a gain or loss during the three or six months ended June 30, 2014, as the outstanding liability-classified warrants were either exercised or had expired. We recorded a gain of $0.3 million and $0.8 million during the three and six months ended June 30, 2013, respectively, related to the change in fair value of the warrant derivative liability during that period. The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions:
			Fair value as of
			June 30, 2013
	Calculated aggregate value (in thousands)		$	1,010
	Exercise price per share of warrant		$	1.5
	Closing price per share of common stock		$	2.15
	Volatility			50	%
	Expected term (years)			0.3
	Risk-free interest rate			0.07	%
	Dividend yield			0	%

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 11 – SUBSEQUENT EVENTS
	In August 2014, we issued an aggregate of 25,000 units to consultants as payment for business and advisory services valued at $20,000 in total. Each unit consists of one share of our common stock, and one-half of one Series D common stock purchase warrant. The units are substantially similar to the units issued in our June 2014 private placement. Each warrant has an exercise price of $1.15 per share, is immediately exercisable and separately transferable from the common shares and expires on the five year anniversary of the date of issuance.
	In August 2014, we issued a total of 189,364 common shares as partial payment for investor and media relations services. We also issued 115,000 common stock purchase warrants and 54,200 common stock purchase options as compensation for business and advisory services. The common stock purchase warrants have an exercise price of $1.15 per share, are immediately exercisable and separately transferable from the common shares and expire on the five year anniversary of the date of issuance.

SUMMARY_OF_CRITICAL_ACCOUNTING1

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses.
	We incurred research and development expenses of approximately $0.9 million and $0.8 million for the three months ended June 30, 2014 and 2013, respectively. We incurred research and development expenses of approximately $2.0 million and $1.6 million for the six months ended June 30, 2014 and 2013, respectively.
Earnings Per Share, Policy [Policy Text Block]	'
	Loss per Share
	Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of June 30, 2014 and 2013, as they would be anti-dilutive:
			Six months ended June 30,
			2014		2013
	Shares underlying options outstanding			8,462,895		5,961,641
	Shares underlying warrants outstanding			20,510,987		8,089,520
	Shares underlying convertible notes outstanding			265,894		257,072
				29,239,776		14,308,233
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.
	Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. We use the Black-Scholes option-pricing model to value our warrant derivative liability which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements
	Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:
	Level 1:	Quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2:	Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
	Level 3:	Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
	A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. We previously recorded a warrant derivative liability for warrants with non-standard anti-dilution provisions. These warrants were either exercised or expired as of June 30, 2014.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).
	Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period.
	Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	Certain prior year balances have been reclassified to conform to current year presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In June 2014, the FASB issued ASU 2014-10 Development Stage Entities (Topic 915). ASU 2014-10 removes all incremental financial reporting requirements from U.S. GAAP for development stage entities. ASU 2014-10 should be applied retrospectively and is effective for fiscal years beginning after December 15, 2014. Early application is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued or made available for issuance. Accordingly, we have decided to adopt ASU 2014-10 early, accordingly all of the past disclosures and presentations for development stage accounting have been eliminated.

SUMMARY_OF_CRITICAL_ACCOUNTING2

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of June 30, 2014 and 2013, as they would be anti-dilutive:
		Six months ended June 30,
		2014		2013
	Shares underlying options outstanding		8,462,895		5,961,641
	Shares underlying warrants outstanding		20,510,987		8,089,520
	Shares underlying convertible notes outstanding		265,894		257,072
			29,239,776		14,308,233

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2014
Supplemental Cash Flow Information [Abstract]	'
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'
	The following table contains additional information for the periods reported (in thousands):
		Six months ended June 30,
		2014		2013
	Non-cash financial activities:
	Common stock options issued as payment of accrued compensation	$	962	$	999
	Derivative liability reclassified to equity upon exercise of warrants		–		55

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Accrued compensation and benefits	$	595	$	1,040
	Accrued research and development		184		82
	Accrued other		203		128
	Total accrued expenses	$	982	$	1,250

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes stock option activity under the Plans:
				Weighted-		Weighted-average		Aggregate
				average		remaining		intrinsic
		Number of		exercise		contractual term		value (in
		shares		price		(in years)		thousands)
	Outstanding at December 31, 2013		6,050,623	$	1.82
	Granted		2,412,272	$	1.34
	Exercised		—		—
	Forfeited		—		—
	Outstanding at June 30, 2014		8,462,895	$	1.69		4.2	$	147
	Exercisable at June 30, 2014		8,207,750	$	1.7		4.2	$	142
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the six months ended June 30, 2014 and 2013:
		Six months ended June 30,
		2014		2013
	Volatility		55.80%		58.90%
	Expected term (years)		3.4		3.9
	Risk-free interest rate		0.50%		0.70%
	Dividend yield		0%		0%

WARRANTS_AND_DERIVATIVE_WARRAN1

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Transactions involving our equity-classified warrants are summarized as follows:
						Weighted-		Weighted-average			Aggregate
						average		remaining			intrinsic
		Number of				exercise		contractual term			value (in
			shares			price			(in years)		thousands)
	Outstanding at December 31, 2013			10,216,597		$	2.56
	Granted			11,315,847		$	0.94
	Exercised			—			—
	Forfeited			-1,021,457		$	2.91
	Outstanding at June 30, 2014			20,510,987		$	1.65			2.2	$	692
	Exercisable at June 30, 2014			20,510,987		$	1.65			2.2	$	692
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	'
	The following table summarizes outstanding common stock purchase warrants as of June 30, 2014:
						Weighted-
						average
		Number of				exercise
			shares			price			Expiration
	Equity–classified warrants
	Issued to consultants			1,163,759		$	2.38		July 2014 through February 2019
	Issued pursuant to 2009 financings			495,059		$	3		July 2014 through September 2014
	Issued pursuant to 2010 financings			1,022,943		$	3.38		January 2015 through May 2015
	Issued pursuant to 2011 financings			1,936,785		$	3.24		January 2016 through April 2016
	Issued pursuant to 2012 financings			296,366		$	3		Dec-17
	Issued pursuant to 2013 financings			4,376,228		$	1.97		December 2017 through August 2023
	Issued pursuant to 2014 financings			11,219,847		$	0.93		March 2015 through June 2019
				20,510,987
Schedule of Share-based Payment Award, Warrants Derivative Liability Valuation Assumptions [Table Text Block]	'
	The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions:
			Fair value as of
			June 30, 2013
	Calculated aggregate value (in thousands)		$	1,010
	Exercise price per share of warrant		$	1.5
	Closing price per share of common stock		$	2.15
	Volatility			50	%
	Expected term (years)			0.3
	Risk-free interest rate			0.07	%
	Dividend yield			0	%

MANAGEMENTS_PLANS_TO_CONTINUE_1

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Management Plan [Line Items]	'	'	'	'
Deficit accumulated during the development stage	$35,930	$32,385	'	'
Cash and Cash Equivalents, at Carrying Value	$4,791	$3,587	$1,500	$2,345
Percentage of Cash and Cash Equivalents in Total Assets	94.00%	'	'	'

SUMMARY_OF_CRITICAL_ACCOUNTING3

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares underlying, outstanding	29,239,776	14,308,233
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares underlying, outstanding	8,462,895	5,961,641
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares underlying, outstanding	20,510,987	8,089,520
Convertible Notes Payable [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares underlying, outstanding	265,894	257,072

SUMMARY_OF_CRITICAL_ACCOUNTING4

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Textual) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Research and Development Expense [Abstract]	'	'	'	'
Research and Development Expense, Total	$924	$792	$2,028	$1,582

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Non-cash financial activities:	'	'
Common stock options issued as payment of accrued compensation	$962	$999
Derivative liability reclassified to equity upon exercise of warrants	$0	$55

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Line Items]	'	'
Accrued compensation and benefits	$595	$1,040
Accrued research and development	184	82
Accrued other	203	128
Total accrued expenses	$982	$1,250

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	$100,000	'
Debt Instrument, Interest Rate, Effective Percentage	4.20%	'
Debt Instrument, Maturity Date	6-Dec-11	'
Debt Instrument, Increase, Accrued Interest	28,000	26,000
Debt Instrument, Convertible, Conversion Price	$0.50	'
Chief Executive Officer [Member]	'	'
Debt Instrument [Line Items]	'	'
Convertible Notes Payable, Total	$200,000	'

CAPITAL_STOCK_AND_STOCKHOLDERS1

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

31-May-14

Feb. 28, 2014

Mar. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Feb. 28, 2014

Jun. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

23-May-14

Investor [Member]

Investor [Member]

Consultant [Member]

Series A Warrant [Member]

Series B Warrant [Member]

Series C Warrant [Member]

Series D Warrant [Member]

Public Offering [Member]

Private Placement [Member]

Series C Common Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

4,163,961

'

686,420

'

776,204

'

10,409,905

'

'

'

'

'

483,125

966,250

'

Warrant percentage to Common Stock

'

8.00%

'

'

'

4.00%

8.00%

'

'

'

'

'

'

'

'

Placement Agent Fee Percentage on Gross Proceeds

'

8.00%

'

'

'

4.00%

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

91,334

'

'

'

'

'

47,800

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

'

$127,000

'

$233,000

'

'

'

$67,000

'

'

'

'

'

'

'

Number of Warrants Exercised

'

'

'

0

200,668

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

0

217,000

'

'

'

'

'

'

'

'

'

'

Warrants Exercised On Cashless Basis

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

Shares Issued During Period Upon Exercise of Warrants

'

'

'

'

537,722

'

326,817

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

Placement Agent Fees and Expense

'

'

'

'

'

'

'

'

'

'

'

'

278,000

'

'

Other Expenses

'

'

'

'

'

'

'

'

'

'

'

'

64,000

'

'

Reimbursement to Placement Agent

'

'

'

$50,000

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

$0.41

$3

'

'

'

$1.15

$0.85

$0.85

$1.15

'

'

'

Shares Issued, Price Per Share

'

'

'

$0.80

'

'

'

'

'

'

'

'

'

$0.80

$0.80

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of shares, Outstanding at beginning of period (in shares)	6,050,623
Number of shares, Granted (in shares)	2,412,272
Number of shares, Exercised (in shares)	0
Number of shares, Forfeited (in shares)	0
Number of shares, Outstanding at end of period (in shares)	8,462,895
Number of shares, Exercisable at June 30, 2014 (in shares)	8,207,750
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$1.82
Weighted-average exercise price, Granted (in dollars per share)	$1.34
Weighted-average exercise price, Exercised (in dollars per share)	$0
Weighted-average exercise price, Forfeited (in dollars per share)	$0
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$1.69
Weighted-average exercise price, Exercisable at June 30, 2014 (in dollars per share)	$1.70
Weighted-average remaining contractual term, Outstanding at June 30, 2014	'4 years 2 months 12 days
Weighted-average remaining contractual term, Exercisable at June 30, 2014	'4 years 2 months 12 days
Aggregate intrinsic value, Outstanding at June 30, 2014 (in dollars)	$147
Aggregate intrinsic value, Exercisable at June 30, 2014 (in dollars)	$142

STOCK_OPTIONS_Details_1

STOCK OPTIONS (Details 1)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility	55.80%	58.90%
Expected term (years)	'3 years 4 months 24 days	'3 years 10 months 24 days
Risk-free interest rate	0.50%	0.70%
Dividend yield	0.00%	0.00%

STOCK_OPTIONS_Details_Textual

STOCK OPTIONS (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$100,000	'	$100,000	'	'	'
Deferred Compensation Share-based Arrangements, Liability, Current	'	'	'	'	962,000	958,000
Allocated Share-based Compensation Expense	$40,000	$71,000	$1,109,000	$1,148,000	'	'
Director [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	106,000	76,000	'	'
Director [Member] | Employee Stock Option [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	1,948,902	1,221,972	'	'
Consultants and Advisors [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	357,370	129,041	'	'
Plan 2009 [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	6,000,000	'	'	'
Plan 2007 [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	6,000,000	'	'	'

WARRANTS_AND_DERIVATIVE_WARRAN2

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of shares, Outstanding at beginning of period (in shares)	10,216,597
Number of shares, Granted (in shares)	11,315,847
Number of shares, Exercised (in shares)	0
Number of shares, Forfeited (in shares)	-1,021,457
Number of shares, Outstanding at ending of period (in shares)	20,510,987
Number of shares, Exercisable at June 30, 2014 (in shares)	20,510,987
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$2.56
Weighted-average exercise price, Granted (in dollars per share)	$0.94
Weighted-average exercise price, Exercised (in dollars per share)	$0
Weighted-average exercise price, Forfeited (in dollars per share)	$2.91
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$1.65
Weighted-average exercise price, Exercisable at June 30, 2014 (in dollars per share)	$1.65
Weighted-average remaining contractual term, Outstanding at June 30, 2014	'2 years 2 months 12 days
Weighted-average remaining contractual term, Exercisable at June 30, 2014	'2 years 2 months 12 days
Aggregate intrinsic value, Outstanding at June 30, 2014 (in dollars)	$692
Aggregate intrinsic value, Exercisable at June 30, 2014 (in dollars)	$692

WARRANTS_AND_DERIVATIVE_WARRAN3

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Equity Classified Warrants [Member]	Equity Classified Warrants [Member]	Equity Classified Warrants [Member]	Equity Classified Warrants [Member]	Equity Classified Warrants [Member]	Equity Classified Warrants [Member]	Equity Classified Warrants [Member]	Equity Classified Warrants [Member]
				Consultant [Member]	Financing 2009 [Member]	Financing 2010 [Member]	Financing 2011 [Member]	Financing 2012 [Member]	Financing 2013 [Member]	Financing 2014 [Member]
Equity-classified warrants [Abstract]	'	'	'	'	'	'	'	'	'	'
Number of shares (in shares)	20,510,987	'	'	1,163,759	495,059	1,022,943	1,936,785	296,366	4,376,228	11,219,847
Weighted Average Exercise price (in dollars per share)	$0.41	$3	$1.15	$2.38	$3	$3.38	$3.24	$3	$1.97	$0.93
Investment Warrants Expiration Date Range Start	'	'	'	31-Jul-14	31-Jul-14	31-Jan-15	31-Jan-16	'	31-Dec-17	31-Mar-15
Investment Warrants Expiration Date Range End	'	'	'	28-Feb-19	30-Sep-14	31-May-15	30-Apr-16	'	31-Aug-23	30-Jun-19
Investment Warrants Expiration Date	'	'	'	'	'	'	'	31-Dec-17	'	'

WARRANTS_AND_DERIVATIVE_WARRAN4

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 2) (Liability Classified Warrants [Member], USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2013
Liability Classified Warrants [Member]	'
Schedule Of Share Based Payment Award Warrants Derivative Liability Valuation Assumptions [Line Items]	'
Calculated aggregate value (in thousands)	$1,010
Exercise price per share of warrant	$1.50
Closing price per share of common stock	$2.15
Volatility	50.00%
Expected term (years)	'3 months 18 days
Risk-free interest rate	0.07%
Dividend yield	0.00%

WARRANTS_AND_DERIVATIVE_WARRAN5

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details Textual) (USD $)	1 Months Ended	3 Months Ended			6 Months Ended
	31-May-14	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Warrants Exercised	'	'	'	'	0	200,668
Warrants Exercised on Cashless Basis	'	'	'	'	'	1,000,000
Shares Issued During Period Upon Exercise of Warrants	'	'	'	'	'	537,722
Stock Issued During Period, Shares, New Issues	4,163,961	'	'	686,420	'	776,204
Derivative, Gain on Derivative	'	'	$300,000	'	'	$800,000
Allocated Share-based Compensation Expense	'	40,000	71,000	'	1,109,000	1,148,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$0.41	$3	'	$0.41	$3
Public Offering [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	'	483,125	'
Consultants [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	'	'	96,000	'
Allocated Share-based Compensation Expense	'	'	'	'	$40,000	$2,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$3	'	'	$3	'
Placement Agent [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	'	326,817	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	'	'	'	18,410
Investor [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Shares Issued During Period Upon Exercise of Warrants	'	'	'	'	326,817	'
Stock Issued During Period, Shares, New Issues	'	'	'	'	10,409,905	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	'	'	71,374	'
Equity Classified Warrants [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	'	10,736,722	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$1.15	'	'	$1.15	'
Equity Classified Warrants [Member] | Maximum [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$1.15	'	'	$1.15	'
Equity Classified Warrants [Member] | Minimum [Member]	'	'	'	'	'	'
Warrants And Derivative Warrant Liability [Line Items]	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$0.85	'	'	$0.85	'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	1 Months Ended	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 28, 2014	Jun. 30, 2014	Jun. 30, 2013
Subsequent Event [Line Items]	'	'	'
Stock Issued During Period, Shares, Issued for Services	91,334	'	'
Stock Issued During Period, Value, Issued for Services	$127	$233	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$0.41	$3
Subsequent Event [Member]	'	'	'
Subsequent Event [Line Items]	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	25,000	'
Stock Issued During Period, Value, Issued for Services	'	$20	'
Subsequent Event [Member] | Common Stock Purchase Warrants [Member]	'	'	'
Subsequent Event [Line Items]	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	115,000	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$1.15	'
Subsequent Event [Member] | Common Stock Purchase Options [Member]	'	'	'
Subsequent Event [Line Items]	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	54,200	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	$1.15	'
Subsequent Event [Member] | Investor [Member]	'	'	'
Subsequent Event [Line Items]	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	189,364	'